Richard Dean Miller, MD | |
943 N Andover Rd, Suite G, Andover, KS 67002-9795 | |
(316) 733-4747 | |
(316) 733-5253 |
Full Name | Richard Dean Miller |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 943 N Andover Rd, Andover, Kansas |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1962464768 | NPI | - | NPPES |
100337800A | Medicaid | KS |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208000000X | Pediatrics | 04-27968 (Kansas) | Primary |
Mailing Address | Practice Location Address |
---|---|
Richard Dean Miller, MD 943 N Andover Rd, Andover, KS 67002-9795 Ph: (316) 733-4747 | Richard Dean Miller, MD 943 N Andover Rd, Suite G, Andover, KS 67002-9795 Ph: (316) 733-4747 |
News Archive
Brain metastatic disease shows branched evolution from the primary tumour, suggest preliminary findings from the largest massively parallel sequencing study of paired samples performed so far.
Using state-of-the-art gene editing technology, scientists from Ann & Robert H. Lurie Children's Hospital of Chicago have discovered a promising target to treat atypical teratoid/rhabdoid tumor (AT/RT) – a highly aggressive and therapy resistant brain tumor that mostly occurs in infants.
Consumers who at least begin the enrollment process before Monday's deadline can avoid the health law's tax penalty, according to this week's Obama administration decision. The change, which some are calling an extension, has triggered some worry from insurers and a round of new attacks from the overhaul's opponents.
When you bump into someone in the workplace or at your local coffee shop, you might call that an "encounter." That's the scientific term for it, too.
Keryx Biopharmaceuticals, Inc. (the "Company") today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of KRX-0401 (Perifosine) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of Clinical Cancer Research.
› Verified 4 days ago